760 related articles for article (PubMed ID: 18261916)
21. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion.
Benlloch S; Galbis-Caravajal JM; Martín C; Sanchez-Paya J; Rodríguez-Paniagua JM; Romero S; Mafe JJ; Massutí B
Cancer; 2006 Oct; 107(8):1859-65. PubMed ID: 16983705
[TBL] [Abstract][Full Text] [Related]
22. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
Oremek GM; Sapoutzis N; Kramer W; Bickeböller R; Jonas D
Anticancer Res; 2000; 20(6D):5095-8. PubMed ID: 11326675
[TBL] [Abstract][Full Text] [Related]
23. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
[TBL] [Abstract][Full Text] [Related]
24. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
Lüftner D; Mesterharm J; Akrivakis C; Geppert R; Petrides PE; Wernecke KD; Possinger K
Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
[TBL] [Abstract][Full Text] [Related]
25. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
26. Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions.
Porcel JM; Salud A; Vives M; Esquerda A; Rodríguez-Panadero F
Clin Biochem; 2005 Nov; 38(11):1031-3. PubMed ID: 15925354
[TBL] [Abstract][Full Text] [Related]
27. [Clinical value of tumor supplied group of factor combined with CEA in diagnosing tuberculosis pleural effusion and malignant pleural effusion].
Li YP; Hu CP; Yang HZ
Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):608-10. PubMed ID: 15804072
[TBL] [Abstract][Full Text] [Related]
28. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of the diagnostic value of telomerase activity with CEA level in benign and malignant pleural effusions].
Yang Z; Xie C
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Apr; 24(4):201-3. PubMed ID: 11802962
[TBL] [Abstract][Full Text] [Related]
30. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
Schneider J; Morr H; Velcovsky HG; Weisse G; Eigenbrodt E
Cancer Detect Prev; 2000; 24(6):531-5. PubMed ID: 11198266
[TBL] [Abstract][Full Text] [Related]
31. New approaches in the diagnostic procedure of malignant pleural effusions.
Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
[TBL] [Abstract][Full Text] [Related]
32. Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions.
Castaño Vidriales JL; Amores Antequera C
Eur J Med; 1992; 1(4):201-7. PubMed ID: 1341445
[TBL] [Abstract][Full Text] [Related]
33. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
Bena-Boupda NF; Rezai SS; Klett R; Eigenbrodt E; Bauer R
Anticancer Res; 2003; 23(6D):5237-40. PubMed ID: 14981996
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma.
Huang WW; Tsao SM; Lai CL; Su CC; Tseng CE
Pathology; 2010 Apr; 42(3):224-8. PubMed ID: 20350214
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A.
Pezzilli R; Migliori M; Morselli-Labate AM; Campana D; Ventrucci M; Tomassetti P; Corinaldesi R
Anticancer Res; 2003; 23(3C):2969-72. PubMed ID: 12926146
[TBL] [Abstract][Full Text] [Related]
36. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
Oremek GM; Gerstmeier F; Sauer-Eppel H; Sapoutzis N; Wechsel HW
Anticancer Res; 2003; 23(2A):1127-30. PubMed ID: 12820359
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
Li YG; Zhang N
Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
[TBL] [Abstract][Full Text] [Related]
38. A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion.
Chierakul N; Kanitsap A; Chaiprasert A; Viriyataveekul R
Respirology; 2004 Mar; 9(1):66-9. PubMed ID: 14982604
[TBL] [Abstract][Full Text] [Related]
39. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
Oremek GM; Eigenbrodt E; Rädle J; Zeuzem S; Seiffert UB
Anticancer Res; 1997; 17(4B):3031-3. PubMed ID: 9329593
[TBL] [Abstract][Full Text] [Related]
40. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]